Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients

Trial Profile

Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 31 Jan 2018 to 2 Mar 2018.
    • 25 Sep 2017 Status changed from recruiting to discontinued.
    • 10 Sep 2017 This trial has been completed in Belgium (End date: 2017-08-31), as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top